vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and JOINT Corp (JYNT). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $15.2M, roughly 1.3× JOINT Corp). JOINT Corp runs the higher net margin — 6.5% vs -541.1%, a 547.6% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs 3.1%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs -28.6%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
AGIO vs JYNT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $15.2M |
| Net Profit | $-108.0M | $991.1K |
| Gross Margin | 90.6% | 81.4% |
| Operating Margin | -608.9% | 4.9% |
| Net Margin | -541.1% | 6.5% |
| Revenue YoY | 86.1% | 3.1% |
| Net Profit YoY | -11.9% | 5510.5% |
| EPS (diluted) | $-1.86 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | $15.2M | ||
| Q3 25 | $12.9M | $13.4M | ||
| Q2 25 | $12.5M | $13.3M | ||
| Q1 25 | $8.7M | $13.1M | ||
| Q4 24 | $10.7M | $14.7M | ||
| Q3 24 | $9.0M | $30.2M | ||
| Q2 24 | $8.6M | $30.3M | ||
| Q1 24 | $8.2M | $29.7M |
| Q4 25 | $-108.0M | $991.1K | ||
| Q3 25 | $-103.4M | $855.0K | ||
| Q2 25 | $-112.0M | $93.4K | ||
| Q1 25 | $-89.3M | $967.8K | ||
| Q4 24 | $-96.5M | $17.7K | ||
| Q3 24 | $947.9M | $-3.2M | ||
| Q2 24 | $-96.1M | $-3.6M | ||
| Q1 24 | $-81.5M | $947.0K |
| Q4 25 | 90.6% | 81.4% | ||
| Q3 25 | 87.0% | 80.1% | ||
| Q2 25 | 86.3% | 79.1% | ||
| Q1 25 | 87.6% | 77.3% | ||
| Q4 24 | 88.3% | 78.4% | ||
| Q3 24 | 91.3% | 90.7% | ||
| Q2 24 | 82.6% | 90.7% | ||
| Q1 24 | 92.3% | 90.9% |
| Q4 25 | -608.9% | 4.9% | ||
| Q3 25 | -907.4% | 1.2% | ||
| Q2 25 | -1020.1% | -8.6% | ||
| Q1 25 | -1222.0% | -5.2% | ||
| Q4 24 | -1165.3% | 5.5% | ||
| Q3 24 | -1146.9% | -1.6% | ||
| Q2 24 | -1228.3% | -5.9% | ||
| Q1 24 | -1124.3% | -1.4% |
| Q4 25 | -541.1% | 6.5% | ||
| Q3 25 | -803.1% | 6.4% | ||
| Q2 25 | -899.4% | 0.7% | ||
| Q1 25 | -1023.3% | 7.4% | ||
| Q4 24 | -899.6% | 0.1% | ||
| Q3 24 | 10574.7% | -10.5% | ||
| Q2 24 | -1115.7% | -11.9% | ||
| Q1 24 | -995.8% | 3.2% |
| Q4 25 | $-1.86 | $0.06 | ||
| Q3 25 | $-1.78 | $0.06 | ||
| Q2 25 | $-1.93 | $0.01 | ||
| Q1 25 | $-1.55 | $0.06 | ||
| Q4 24 | $-1.44 | $0.01 | ||
| Q3 24 | $16.22 | $-0.21 | ||
| Q2 24 | $-1.69 | $-0.24 | ||
| Q1 24 | $-1.45 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $23.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $15.1M |
| Total Assets | $1.3B | $61.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | $23.6M | ||
| Q3 25 | $92.7M | $29.7M | ||
| Q2 25 | $80.9M | $29.8M | ||
| Q1 25 | $79.0M | $21.9M | ||
| Q4 24 | $76.2M | $25.1M | ||
| Q3 24 | $253.7M | $20.7M | ||
| Q2 24 | $84.5M | $17.5M | ||
| Q1 24 | $118.8M | $18.7M |
| Q4 25 | $1.2B | $15.1M | ||
| Q3 25 | $1.3B | $22.7M | ||
| Q2 25 | $1.4B | $23.2M | ||
| Q1 25 | $1.5B | $22.8M | ||
| Q4 24 | $1.5B | $20.7M | ||
| Q3 24 | $1.6B | $20.5M | ||
| Q2 24 | $660.5M | $23.2M | ||
| Q1 24 | $743.9M | $26.2M |
| Q4 25 | $1.3B | $61.0M | ||
| Q3 25 | $1.4B | $69.4M | ||
| Q2 25 | $1.5B | $73.2M | ||
| Q1 25 | $1.6B | $80.1M | ||
| Q4 24 | $1.7B | $83.2M | ||
| Q3 24 | $1.8B | $79.6M | ||
| Q2 24 | $773.1M | $82.4M | ||
| Q1 24 | $849.7M | $85.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $1.8M |
| Free Cash FlowOCF − Capex | $-97.3M | $334.7K |
| FCF MarginFCF / Revenue | -487.5% | 2.2% |
| Capex IntensityCapex / Revenue | 5.6% | 9.9% |
| Cash ConversionOCF / Net Profit | — | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | $-1.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | $1.8M | ||
| Q3 25 | $-88.2M | $1.8M | ||
| Q2 25 | $-77.1M | $868.6K | ||
| Q1 25 | $-111.5M | $-3.7M | ||
| Q4 24 | $-133.2M | $9.4M | ||
| Q3 24 | $-84.2M | $3.4M | ||
| Q2 24 | $-72.6M | $-973.5K | ||
| Q1 24 | $-99.9M | $2.8M |
| Q4 25 | $-97.3M | $334.7K | ||
| Q3 25 | $-89.7M | $1.5M | ||
| Q2 25 | $-78.0M | $363.6K | ||
| Q1 25 | $-112.3M | $-4.0M | ||
| Q4 24 | $-134.1M | $8.2M | ||
| Q3 24 | $-84.6M | $3.2M | ||
| Q2 24 | $-72.7M | $-1.2M | ||
| Q1 24 | $-100.0M | $2.4M |
| Q4 25 | -487.5% | 2.2% | ||
| Q3 25 | -696.5% | 10.9% | ||
| Q2 25 | -626.2% | 2.7% | ||
| Q1 25 | -1286.4% | -30.8% | ||
| Q4 24 | -1250.1% | 55.9% | ||
| Q3 24 | -944.2% | 10.6% | ||
| Q2 24 | -844.4% | -4.1% | ||
| Q1 24 | -1221.2% | 8.1% |
| Q4 25 | 5.6% | 9.9% | ||
| Q3 25 | 12.1% | 2.4% | ||
| Q2 25 | 7.0% | 3.8% | ||
| Q1 25 | 8.8% | 2.5% | ||
| Q4 24 | 9.0% | 8.1% | ||
| Q3 24 | 4.7% | 0.8% | ||
| Q2 24 | 1.8% | 0.9% | ||
| Q1 24 | 1.7% | 1.3% |
| Q4 25 | — | 1.86× | ||
| Q3 25 | — | 2.07× | ||
| Q2 25 | — | 9.30× | ||
| Q1 25 | — | -3.82× | ||
| Q4 24 | — | 532.98× | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGIO
Segment breakdown not available.
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
